A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood

• Publication date

  2016-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2015-06-650226PMID 26626991PMCID PMC4817308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MP19-01 DEVELOPMENT OF THE SHORT FORM OF THE WISCONSIN STONE QUALITY OF LIFE (WISQOL) QUESTIONNAIRE FOR ASSESSING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH UROLITHIASIS

  2021cited by this paper
• Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

  2015influential reference
• Changing paradigm of prophylaxis with longer acting factor concentrates

  2014cited by this paper
• Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

  2014influential reference
• A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?

  2014cited by this paper
• Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

  2014cited by this paper
• Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

  2014cited by this paper
• Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

  2014cited by this paper
• Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

  2014cited by this paper
• Guidelines for the management of hemophilia

  2013cited by this paper
• A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

  2013cited by this paper
• Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

  2013cited by this paper
• Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

  2013influential reference
• Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

  2013cited by this paper
• Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

  2013cited by this paper
• A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

  2012influential reference
• Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification

  2012cited by this paper
• Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

  2012cited by this paper
• Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

  2011cited by this paper
• Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

  2010cited by this paper
• Reduced elimination of IgG antibodies by engineering the variable region.

  2010cited by this paper
• Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

  2008cited by this paper
• Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

  2007cited by this paper
• A randomized, double‐blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation

  2007cited by this paper
• Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

  2007cited by this paper
• Practice patterns in haemophilia A therapy – global progress towards optimal care

  2006cited by this paper
• A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects

  2005cited by this paper
• Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A

  2004cited by this paper
• Monitoring the bioavailability of FEIBA with a thrombin generation assay

  2003cited by this paper
• Haemophilia prophylaxis in young patients–a long‐term follow‐up

  1997cited by this paper
• Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

  1994cited by this paper

• Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.

  2026cites this paper
• Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables

  2025cites this paper
• Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions

  2025cites this paper
• [Application value of thromboelastography in assessing coagulation function in children with severe hemophilia A after emicizumab therapy: a single-center study].

  2025cites this paper
• Small-intestinal obstruction due to intramural hematoma in a child with hemophilia A.

  2025cites this paper
• Comparative ex vivo analysis of Mim8 in thrombin generation assays triggered by activated factor XI or tissue factor

  2025cites this paper
• A First-in-Human Study of NXT007, a Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, in Healthy Participants.

  2025cites this paper
• Laboratory Assessment of Emicizumab Levels in Hemophilia A: Influence of Assay Selection on Reported Results

  2025cites this paper
• Beyond coagulation: Coagulation protease factor VIIa in cytoprotective response.

  2025cites this paper
• Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A.

  2025cites this paper
• Effectiveness of Octocog Alfa (BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset, Including Under‐Represented Subgroups

  2025cites this paper
• More real-world evidence on the impact of emicizumab

  2025cites this paper
• A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors

  2025cites this paper
• Use of antithrombotic therapy in patients with hemophilia: A selected synopsis of the EHA-ISTH-EAHAD-ESO Clinical Practice Guidance document.

  2024cites this paper
• L’ère des nanocorps et anticorps thérapeutiques en hémostase

  2024cites this paper
• Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A

  2024cites this paper
• Comprehensive Evaluation of Anti-Emicizumab Antibodies in Acquired Hemophilia A: A Detailed Case Study and Methodological Evaluation.

  2024cites this paper
• Implementing an Assay Detecting Anti-drug Antibody against Emicizumab: Experience from One Center in France

  2024cites this paper
• Utilization of phase I studies for target validation of first-in-class drugs.

  2024cites this paper
• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience

  2024cites this paper
• Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center

  2024cites this paper
• Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype

  2024cites this paper
• Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis

  2024influential citation
• Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A

  2024influential citation
• Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia.

  2024cites this paper
• In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia

  2024cites this paper
• Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A

  2024cites this paper
• Concizumab improves clot formation in hemophilia A under flow.

  2024cites this paper
• Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

  2024cites this paper
• Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience

  2023cites this paper
• Clinical pharmacology of emicizumab for the treatment of hemophilia A

  2023influential citation
• The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A

  2023cites this paper
• Emicizumab: the hemophilia A game changer.

  2023cites this paper
• Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults

  2023cites this paper
• NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V

  2023cites this paper
• Coagulopathy of liver disease-a pathophysiologic rebalance of hemostasis and thrombosis.

  2023cites this paper
• Comparison of the Incidence of Adverse Events Between Japanese and Non-Japanese Healthy Subjects in Phase I Studies: A Systematic Review and Meta-Analysis

  2023cites this paper
• Between Scylla and Charybdis: thrombosis in children with hemophilia

  2023cites this paper
• In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.

  2023cites this paper
• Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance

  2023cites this paper
• Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis

  2023cites this paper
• Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

  2023cites this paper
• Hemophilia A: Emicizumab monitoring and impact on coagulation testing.

  2023cites this paper
• Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time–based clotting time test results in patients treated with emicizumab

  2023cites this paper
• Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine

  2023cites this paper
• Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks

  2023cites this paper
• Low-dose Emicizumab prophylaxis in severe haemophilia A patients -a retrospective study bringing new hope for our patients.

  2023cites this paper
• Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis

  2023cites this paper
• Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan

  2023cites this paper
• Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma

  2023cites this paper
• Acquired Hemophilia A: A Permanent Challenge for All Physicians

  2022cites this paper
• Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy

  2022cites this paper
• Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

  2022cites this paper
• Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review

  2022cites this paper
• Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report

  2022cites this paper
• AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors

  2022cites this paper
• Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

  2022cites this paper
• Current and future therapies for haemophilia—Beyond factor replacement therapies

  2022cites this paper
• Sensitive Measurement of Clinically Relevant Factor VIII Levels in Thrombin Generation Assays Requires Presence of Factor XIa

  2022cites this paper
• Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review

  2022cites this paper
• Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications

  2022cites this paper
• Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis.

  2022cites this paper
• Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases

  2022cites this paper
• Development of simple and rapid method for Emicizumab quantification by LC-MS/MS in human plasma.

  2022cites this paper
• Consensus recommendations on appropriate coagulation tests during emicizumab administration in Saudi Arabia.

  2022cites this paper
• The More Recent History of Hemophilia Treatment.

  2022cites this paper
• Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review

  2022cites this paper
• Opportunities and challenges of bi-specific antibodies.

  2022cites this paper
• AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study

  2022cites this paper
• Heterogeneous coagulant potential of emicizumab in neonatal factor VIII–deficient plasma

  2022cites this paper
• Non‐factor therapies for bleeding disorders: A primer for the general haematologist

  2022cites this paper
• Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules

  2022cites this paper
• Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement.

  2022cites this paper
• The Implication of New Developments in Hemophilia Treatment on Its Laboratory Evaluation

  2022cites this paper
• Hemophilia: The Past, the Present, and the Future.

  2021cites this paper
• Factor VIII products: key aspects of development, clinical research and use (part 1)

  2021cites this paper
• Studies on factor VIII toward a new therapeutic for hemophilia A

  2021cites this paper
• In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients

  2021cites this paper
• Clinical case of an infant with severe hemophilia A on emicizumab

  2021cites this paper
• Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A

  2021cites this paper
• Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings

  2021cites this paper
• Recent Advances in the Treatment of Hemophilia: A Review

  2021cites this paper
• Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review

  2021cites this paper
• Bispecific antibodies: A promising entrant in cancer immunotherapy

  2021cites this paper
• Лекарственные препараты фактора VIII, актуальные вопросы разработки, клинического исследования и применения (часть 1)

  2021cites this paper
• A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A

  2021cites this paper
• Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen

  2021cites this paper
• Bispecific antibodies for the treatment of hemophilia A

  2021influential citation
• Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

  2021cites this paper
• Approximation of emicizumab plasma levels in emergency situations. A practical approach

  2021cites this paper
• Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study

  2021cites this paper
• BTT_A_252580 221..235

  2021cites this paper
• Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors

  2021cites this paper
• Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors

  2021cites this paper
• Discovery and Development of Emicizumab ( HEMLIBRA ®  ): A Humanized Bispecific Antibody to Coagulation Factors IXa and X with a Factor VIII Cofactor Activity

  2021cites this paper
• Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors

  2020cites this paper
• Multispecific, Multivalent Antibody‐Based Molecules Engineered on the DART® and TRIDENTTM Platforms

  2020cites this paper
• Chapter 4: Production Strategies and Challenges with IgG-Based Bispecific Ab Formats

  2020cites this paper
• The Art of Detecting Antibodies against Factor VIII

  2020cites this paper
• Laboratory testing in hemophilia: Impact of factor and non‐factor replacement therapy on coagulation assays

  2020cites this paper